Maintain core position, do not add at 111.59, keep the 103 hard stop, execute 20-30% trim into 116-118 strength.

• Operating margin recovery may take an extra quarter or two; Q3 could print at 14% vs the expected 18%
• Net debt increased 6x from $4.4 billion to $27.2 billion in a single quarter, creating real constraints on buyback capacity
• If integration underperforms, the 2.3x net debt/EBITDA becomes 3.0x-3.5x before any deleveraging occurs
• The stock ran 37% off the May low before technical indicators began flashing caution (MACD bearish cross, price below 10 EMA, RSI falling from 78)
• A break below the 10 EMA would likely test the 50 SMA and the 103 hard stop
• Libre Duo FDA approval, Medtronic MiniMed partnership, and Medicare CGM decision are potential catalysts, not confirmed drivers; commercialization takes quarters and outcomes are binary
• Citadel's 13F position increase from Q2 is stale information by late August and cannot substitute for price action confirmation
• A hawkish macro surprise creates drawdown risk for defensive names through multiple compression, not immunity
• Waiting for confirmation (not adding at 111.59) creates asymmetric risk: 7.6% opportunity cost if stock reaches 120 vs 7.6% realized loss if stop at 103 is hit, but the loss is real while the opportunity cost is theoretical
• Dropping the trim directive would eliminate protection against the scenario where the breakout above 118 fails

→ vs neutral: Margin compression is a one-time event to look through; the aggressive view assumes recovery happens on schedule, but integration costs always run longer and Q3 could come in at 14% margins instead of 18%

→ vs neutral: The 2.3x net debt/EBITDA is treated as a stable endpoint; the conservative view treats it as a vulnerability that hasn't yet been tested—integration underperformance could push it to 3.0x-3.5x

→ vs neutral: MACD bearish cross, price below 10 EMA, and RSI cooling from 78 are dismissed as meaningless noise; these indicators are flashing caution precisely after a 37% run and should trigger trim discipline, not complacency

→ vs neutral: Catalyst stack (Libre Duo FDA, Medtronic MiniMed, Medicare CGM) treated as confirmed upside drivers; they are potential drivers that may not materialize on schedule or scope

→ vs neutral: Institutional flow (hedge fund 13F) cited as a market signal; this information is stale by late August and cannot substitute for actual price action confirmation

→ vs neutral: Hawkish Jackson Hole surprise framed as a defensive rotation tailwind; defensive names still sell off on multiple compression in genuine risk-off events regardless of low beta

→ vs aggressive: Proposed to raise add trigger from 103 to 107-110; if the pullback extends to 107 with MACD still bearish and RSI still falling, 107 is not a better entry than 103—the cost of waiting is capped, the cost of adding prematurely is not

→ vs aggressive: Proposed to tighten the hard stop only after confirmed breakout above 118; this leaves an open-ended commitment without defined downside protection when technical signals are already deteriorating

→ vs aggressive: Proposed to drop the trim directive entirely or defer until Medicare decision; this eliminates capital protection against the scenario where the breakout fails and the rally is given back entirely

HOLD core position; trim 15% on confirmed test of 118 with volume above 10 million shares; add trigger at 105-108; hard stop at 103

• Forward P/E at 18.4 means temporary 12.1% operating margin compression is already priced in
• Net debt increased 6x from 4.4B to 27.2B in one quarter, limiting buyback capacity and creating refinancing exposure
• 37% rally off the May low with RSI cooling from 78, MACD bearish cross, and price below 10 EMA signal healthy pullback rather than breakdown
• Two of three catalysts confirmed: Libre Duo FDA authorization and Medtronic MiniMed launch; Medicare decision remains binary and pending
• Support confluence at 105-108: 200 SMA at 105.71, August 3 breakout level, and lower Bollinger band at 103.61 below
• Ken Griffin's 547% Q2 stake increase is stale by late August and one hedge fund's positioning is not a market signal
• Macro is a wash for ABT given 0.58 beta - neither tailwind nor headwind on hawkish or dovish scenarios
• 103 hard stop defines maximum loss; aggressive's deferral creates open-ended downside during momentum deterioration

→ vs aggressive: Forward P/E at 18.4 indicates temporary margin pain already priced in; adding at 111.59 is not buying a bargain but paying fair value for an accepted integration story

→ vs aggressive: 6x leverage increase from 4.4B to 27.2B limits buyback capacity during historically most accretive repurchase window and creates refinancing exposure

→ vs aggressive: Technical signals after 37% rally are information, not noise; ignoring MACD bearish cross, price below 10 EMA, and RSI cooling creates risk of adding at 112 and watching it decline to 108

→ vs aggressive: Libre Duo approval and Medtronic partnership are confirmed catalysts; Medicare decision is binary and pending - not all three are confirmed upside drivers

→ vs aggressive: Institutional flow overreliance; Ken Griffin's 547% Q2 increase is stale by late August and single hedge fund positioning is not a market signal

→ vs aggressive: Trim directive is not backwards; harvesting 15-20% into confirmed strength at 116-118 resistance zone protects capital against failed breakout scenario

→ vs conservative: Technical signals indicate basing, not breakdown; RSI held above 50, 50 SMA approaching golden cross with 200 SMA, stock in recovery trend doing what recovery trends do

→ vs conservative: Conservative framework incorrectly reads indicators as trend-change warnings when they apply to a stock in a recovery resetting before the next leg

→ vs conservative: Both conservative and aggressive miss that two of three catalysts are already commercial realities, not merely potential upside

→ vs conservative: Cost of waiting is capped; 103 may not come; synthesis add zone at 105-108 captures higher-probability confluence without demanding full retest of May low